When I read stories that appear throughout the book, the room becomes pin-drop silent. Not uncomfortable, but attentive. People lean forward. Some close their eyes. Others quietly wipe away tears. Even after reading these stories again and again, my own eyes still mist. These are not reactions to theory or argument. They are responses to a painful reality many recognize.

What becomes clear in those rooms is that the frustration is not isolated to one role or perspective. Patients speak about waiting and uncertainty. Clinicians describe exhaustion and moral strain. Innovators and policymakers wrestle with systems that move more slowly than the problems they are trying to solve. The details differ, but the throughline is the same: people want care that recognizes their presence and treats them as more than a process to be managed. When that recognition happens, the tone of the conversation changes.

Since its listing, the book has spent several consecutive weeks on Amazon’s Top New Releases list. That matters in a conventional sense. Still, rankings, whether in print or digital format, do not explain what happens when people hear their own experience reflected back to them with clarity and respect. Stories do that work. Many are weary of facts and figures deployed to justify positions rather than illuminate lived reality.

Human experience carries a different kind of truth. It does not compete with data, but it precedes it. When experience is named accurately, people do not feel persuaded. They feel recognized. That recognition opens space for reflection, dialogue, and ultimately for change.

A Question That Changes the Room

I finished a book talk and signing with The Marfan Foundation, and the impact lingers beyond the formal program. During the signing, people ask thoughtful, personal questions. I often ask permission to respond by reading a short passage from the book. Then I listen to stories of courage, love, and endurance that surface naturally and without prompting.

Parents speak about children. Siblings talk about one another. Families describe navigating medical uncertainty and emotional trauma over years, sometimes decades. Individuals share how they discover the strength they did not know they possessed, and how they learn to share that strength with others walking similar paths. These are not stories of abstraction. They are lived, detailed, and deeply human.

The Marfan Foundation is one of the patient and professional communities reflected in the book, and in the room, the reason is unmistakable. Physicians are spoken of by first name – Alan, Duke, Kim and Reed – not title. They are described not as distant experts, but as people who show up consistently and with care. These stories remind everyone present that even in the most complex conditions, care is sustained by relationships as much as by scientific excellence.

Between Two Meetings, on a Moving Train

As I board a Brightline train for the next meeting, the contrast stays with me in a quiet, persistent way. I am traveling from a gathering centered on shared human experience to SCOPE Summit 2026, a global convening focused on clinical trials and research infrastructure. The agenda centers on development planning, protocol optimization, patient-centric trial design, site engagement and recruitment, generative AI, and the technologies that move science from hypothesis to evidence.

One meeting is rooted in lived journeys, where science is received as hope amid uncertainty. The other is grounded in structure and precision, where science is designed, measured, and scaled. Both spaces matter deeply, and both are essential to progress. Clinical research is where rigor lives and where uncertainty is reduced in ways that allow care to advance responsibly.

Yet the transition between these two gatherings and two cities reveals something essential. People do not leave their humanity at the door of the operating room or the halls of science. They carry it with them into protocols, endpoints, enrollment decisions and trial participation. Patients do not experience trials as abstractions. They experience them as acts of trust layered onto already complex lives.

When Structure Forgets Experience

Too often, human experience is treated as something to be accounted for after systems are built, rather than as a foundation for their design. Trials are optimized for efficiency and compliance, yet struggle when recruitment falters, participation drops, or trust erodes. These outcomes are not solely technical failures. They are relational failures.

Patient-centric trial design is not a feature added late in development. It is a mindset that shapes questions, assumptions, and priorities from the start. Site engagement is not a procedural step, but a relationship built over time. Technology reduces burden only when shaped by empathy, context, and understanding.

Rare disease communities such as The Marfan Foundation understand this instinctively. When systems fall short, patients and families organize, advocate, and collaborate more intentionally. In doing so, they model what the broader system aspires to scale: trust, continuity, shared language, and partnership. People do not fragment their lives the way systems fragment care.

When Experience Finally Counts

At SCOPE, this question becomes practical rather than theoretical. I moderate a fireside chat with StuffThatWorks executives Yael Elish and newly appointed CEO Julie Ross, exploring what happens when patient experience is treated not as a marginal input but as the foundation of artificial intelligence itself. Billions of dollars are invested in pre-clinical discovery, yet clinical trials remain a costly bottleneck, often stretching beyond seven years before therapies reach patients.

One story from the book captures why this matters. A woman living with a chronic autoimmune condition follows treatment guidelines faithfully yet struggles with side effects that force her to stop therapy repeatedly. Her medical record reflects non-adherence, not struggle. It is only when she joins a patient-driven community where thousands share lived experience that patterns emerge her clinicians have never seen.

Within weeks, she learns how others adjust dosing, manage side effects, and balance treatment with daily life. When these experiences are aggregated and analyzed, they do not contradict clinical science. They complete it. What once looks like noise becomes a signal when the human story is allowed to remain intact.

This is why patient-derived models matter. Real-world evidence is not simply post-market surveillance. It is the accumulated story of how people actually live with disease, navigate treatment, and make trade-offs that controlled environments rarely capture. These data are not neutral artifacts. They are lives rendered into patterns with meaning.

Restoring What Was Lost

What I witness in quiet rooms, at signing tables, and in conversations that follow readings is not resistance to science. I see the same truth as a fireside chat moderator, alongside people dedicated to bridging patient voice, data, and science in ways that honor those it seeks to serve. What emerges, again and again, is a longing for connection.

People are not asking to be spared complexity, nor do they believe science belongs only in a sterile laboratory. They are asking not to be erased by it. They want science that recognizes them even as it advances, and systems that remember who they are designed to serve.

This is where Why People Matter ultimately resides. Healing does not begin when systems are optimized or when data moves faster. It starts when relationships are restored and when people feel recognized within the structures meant to help them. Science advances when trust is present, and trust grows when listening is treated not as an accessory but as a foundation.

If there is a path forward, it is not found by choosing between humanity and innovation. It is found by refusing to separate them. Data matters because people do. And when science remembers that progress becomes worthy of the lives it touches.

The post Why Healing Still Begins with Relationship appeared first on Medika Life.

Doctors are evaluated on patient throughput, not the depth of their engagement. Pharmaceutical and medical device companies create and perfect new products for patients but often neglect their preferences, stated needs, and lived experiences in recruitment and development efforts.

Real-world evidence (RWE), a promising frontier in health settings from innovation to care decisions, is poised to change this dynamic. If we are open to acting upon it, it can become the basis for centering efforts directly on the patient experience.

As a father and caregiver, I’ve walked this journey firsthand. My child’s health challenges have brought me face-to-face with the limitations of a system that often measures success in drugs prescribed rather than resolutions achieved. I’ve seen the toll that rushed consultations and fragmented care take on families searching for answers. It is a stark reminder that even as the science of medicine advances, the art of listening lags.

Recently, we visited a doctor’s office to consult about our young adult’s rare disease. We hired a patient advocate to bridge the chasm between clinical expertise and lived experience. They translate medical jargon, connect patients with appropriate specialists, and, most importantly, validate the patient’s voice.

Listening to the advocate prompted me to ask a critical question about this complex clinical case: “What is the underlying cause of the symptoms?”When our non-medically trained patient advocate suggested surgery to address the root causes of our child’s GI problems, one doctor we consulted, who came from a noted teaching hospital, confronted us.

“Who are you going to believe,” he asked. A patient or me?”  Ultimately, the patient advocate, who consulted with other patients and their physicians, was spot-on. The operation took place; the outcome was outstanding. That is the power of RWE as a catalyst for objective conversation.

Real-World Evidence: A Catalyst for Change

The Food and Drug Administration (FDA) defines RWE as “the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD).” These data include electronic health records, insurance claims, and patient-generated information from mobile health apps and wearable devices. Unlike randomized controlled trials, which too often exclude diverse populations, RWE provides a more comprehensive view of how treatments perform in real-world settings.

Physicians face immense pressure to see more patients in less time. Emergency physicians, for example, are expected to see 2.4 to 3.3 patients per hour, while family doctors might handle 3.3 patients or more per hour in high-volume settings. These metrics may boost productivity, yet at the same time, often come at the expense of meaningful patient interactions. The result? Missed opportunities to understand the full scope of a patient’s experience and even the true nature of the problem.

Empowering Patients and Data

One possible example of how RWE can prioritize the patient’s voice is StuffThatWorks, a platform founded by Yael Elish, one of the founders and executives of the consumer navigational company WAZE. Like WAZE, StuffThatWorks uses AI-powered crowdsourcing to connect individuals with similar diagnoses, enabling them to share experiences and generate actionable insights into treatments and outcomes. It’s a patient-led approach that democratizes data collection, making it richer and more representative. For sponsors of medical trials, the platform offers the chance to harness a massive customer focus group, gaining access to the voices of millions of people struggling with health concerns ranging from treatment to anxiety around illness to the cost burden of sickness.

StuffThatWorks – collaborating with companies and patient organizations, recently began collaborating with The Marfan Foundation, highlighting the potential to engage non-profits in leveraging RWE to benefit global disease communities. Similarly,  The StuffThatWorks partnership with Advanced Clinical, a major research services and clinical resourcing organization, allows project teams to engage with patients directly through surveys and focus groups, enhancing patient participation in clinical research. These initiatives demonstrate the transformative power of intentionally centering patient experiences in healthcare innovation.

More and more, leading academic hospitals such as Weil Cornell Medical Center’s Genetics and Personalized Cancer Prevention Department in New York City are recognizing that care extends beyond cutting-edge medicine and outstanding physicians—it calls for experts who have been on frontlines—as patients and counselors.

“I feel fortunate to bring my real-world experience as a patient to my work as a provider,” says Emily Epstein, LMSW, Genetic Social Worker/Clinical Behavioral Health Care Specialist at Weill Cornell. “This deep understanding of the patient journey inspired me to create a role where I can offer the very support I once advocated for, rooted in true empathy and knowledge. Real-world patient experience is essential to transforming healthcare, infusing it with humanity, compassion, and meaningful change—ensuring we honor and serve both the science of medicine and humanity at its heart.”

Chief Patient Officers

Several pharmaceutical and clinical research companies have established Chief Patient Officer (CPO) roles, recognizing the importance of patient engagement. Parexel, for example, appointed Stacy Hurt as a CPO to lead patient advocacy efforts. Hurt says, “Parexel’s priority focus is on providing patient-centered solutions that enhance the clinical trial experience and make participation more accessible to everyone.”  A health professional who is both a cancer survivor and a caregiver for her son, Hurt brings a patient’s perspective to the work.  Companies like Merck, Pfizer, Sanofi, and Astellas have also created similar roles, signaling a broader industry commitment toward integrating patient insights into drug development.

The National Health Council emphasizes that as RWE becomes a cornerstone of health decision-making, the experience and needs of patients must be prioritized, not addressed as an afterthought. Integrating RWE into the health system can enhance treatment efficacy, safety, and patient satisfaction. However, this requires more than technological innovation; it demands a cultural shift within the healthcare ecosystem.

Now What?

Reflecting on my child’s medical journey and the rise of patient advocacy communities that began to take form during the HIV epidemic and that patient community’s vocal demand to be included in conversations about drug development and news flow, it’s clear that the journey toward patient-centered care is still at an awkward early stage.

Platforms like StuffThatWorks offer a glimpse into what’s possible when prioritizing patient voices. By fostering communities where individuals can share their experiences, these tools generate valuable data and empower patients to take an active role in their care.

Let us commit to creating a health system where every patient’s story is heard, valued, and acted upon. By doing so, we honor the science of medicine and humanity at its heart.

The post Real-World Evidence Unlocks Consumer Voice to Improve Care appeared first on Medika Life.

In 2017, an International Classification aimed to provide clarity to health professionals, patients, and researchers emphasizing the distinction of vascular complications, particularly the extraordinarily elevated risk of aortic dissection – at least 250x that of the general population with most VEDS patients experiencing a life-threatening vascular event before age 40.

Unfortunately, the health community has not yet fully appreciated that each of the 13 subtypes are different and need to be treated as individual entities. For those subtypes that are life-threatening – like VEDS — that realization can be the difference between life and death. Delays in diagnosis and treatment continue, which significantly heighten patient danger.

Too few providers know enough about VEDS beyond distant memories of a line or two in a med school textbook. Fewer still understand that VEDS can kill within hours when misdiagnosed. In the case of aortic dissection, recognizing VEDS – particularly in the young whose presentation often confounds providers until it’s too late – is essential.  Ordering a stat CT scan and follow-up emergency surgery can literally mean the difference between life and death.

The multiple authors of the 2017 classification note: “Even for experienced clinicians, the clinical diagnosis of VEDS may be difficult. Because of implications for treatment, natural history, and recurrence risk, the diagnosis of VEDS rests on the identification of a causative mutation in the COL3A1.”

The classification, which now recognizes 13 subtypes of EDS, was a concerted effort by the medical community to bring order to a complex array of symptoms and genetic variations. Experts deliberated over whether to maintain a clinically oriented classification, focusing on how symptoms present in patients, versus a genetic classification, which groups conditions based on their genetic causes. Ultimately, the decision was made to preserve the clinical approach, and descriptive names—such as hypermobile EDS (hEDS), classical EDS (cEDS), and vascular EDS (VEDS)—were recommended for use in medical, scientific, and patient communities. 

Albeit symbolic, it is crucial to highlight the risks and urgency of Vascular Ehlers-Danlos Syndrome by capitalizing the “v” in vascular. This underscores the vital role of patient and physician advocates in raising awareness about a condition that can save lives if treated promptly and correctly.  Groups like The Marfan Foundation and its ties to the VEDS community serve as rallying points for much-needed conversation and awareness, empowering the audience to take action in the rare disease community.  Meanwhile, massive real-world evidence platforms that capture millions of patient voices, such as StuffThatWorks, are shifting to the “cap V” to underscore essential change.

Vascular EDS is not simply a subtype of a rare disease; it is a ticking time bomb. It is a condition that can lead to sudden death due to ruptured arteries, bowel perforations, and other catastrophic vascular events. Despite this, VEDS is grouped alongside other, less life-threatening – albeit life-altering and dangerous – forms of EDS, potentially diminishing the urgency required for diagnosis and treatment. Misinterpretation within the medical community that all EDS subtypes are the same leads to the underdiagnosis of VEDS, particularly in emergency room settings – an oversight that can cost lives.

The Challenge of Recognizing VEDS in a Subtype Framework

EDS is a genetic connective tissue disorder that affects the body’s ability to produce collagen in all its forms. However, the severity of symptoms across the 13 subtypes varies dramatically. Hypermobile EDS, a common form, causes joint hypermobility, chronic pain, gastrointestinal distress, and frequent dislocations. These symptoms are undoubtedly life-altering, but they are not immediately life-threatening. Vascular EDS, on the other hand, is a condition in which the walls of the arteries, intestines, and uterus can spontaneously rupture, often without warning, and the outcome – without correct and speedy intervention – can be fatal.

For patients with VEDS, life is precarious. A seemingly routine day can turn fatal with the rupture of a major blood vessel. The median life expectancy of those with VEDS is between 48 and 51 years, with many patients dying from catastrophic internal bleeding in their 20s and 30s or even younger. When VEDS patients arrive at the emergency room, their symptoms—such as abdominal pain or chest discomfort—are too often misdiagnosed. Without the immediate realization that these patients are experiencing vascular events, the consequences are usually fatal. 

Yet, the fact that VEDS is listed as a “subtype” of EDS may be one reason emergency room physicians are not diagnosing these cases correctly or not engaging with urgency. By classifying VEDS under the same scroll-down subtype as other EDS forms, its severity can be overlooked. Medical professionals might be familiar with the musculoskeletal manifestations of hEDS. Still, they may not be fully aware of the life-threatening risks that VEDS patients confront daily. This lack of awareness or confusion can lead to misdiagnosis, mistreatment, and (preventable) death.

Subtype Thinking and Physician Engagement: A Fatal Disconnect

While designed for clarity, there is a growing concern among people diagnosed with Vascular EDS that the subtype classification system contributes to a lack of urgency in diagnosing their illness. Medical schools and residency programs are still catching up with the intricacies of rare disease training, and the medical community is often overwhelmed by the complexities of EDS.

Presented with 13 subtypes, physicians might reasonably think that all forms of EDS are similar—chronic, difficult to manage, but not necessarily life-threatening. This perception creates a dangerous environment for VEDS patients, whose symptoms can escalate to fatal events without immediate, specialized care.

Moreover, the reclassification might minimize the visibility of VEDS within medical education and patient care discussions. When grouped with other EDS types, VEDS is often viewed through the same clinical lens, with less emphasis on its unique risks. This reduces awareness and limits the resources dedicated to VEDS-specific training for healthcare professionals. The consequences are real and devastating: emergency room doctors may not consider VEDS as a potential diagnosis until it’s too late, leading to fatal outcomes that could have been prevented with earlier recognition.

The Consequences in Emergency Care: A Case for Better Awareness

Emergency rooms are high-pressure environments where decisions must be made quickly. A VEDS patient might come in with symptoms such as a sudden, severe headache, chest pain, or abdominal discomfort. In the absence of a known diagnosis, these symptoms can be attributed to common ailments like migraines, heartburn, or indigestion. However, in a VEDS patient, these symptoms can be early indicators of a ruptured artery or bowel, requiring immediate, life-saving intervention.

For emergency physicians, recognizing these red flags is crucial. Yet, studies show that rare diseases are often underrepresented in medical education, and this lack of knowledge can have fatal consequences. In the case of VEDS, a patient’s life may depend on whether a physician is familiar with the condition. Sadly, many VEDS patients report being dismissed or misdiagnosed when they seek emergency care, only to experience catastrophic events shortly after leaving the hospital.

In the case of people with undiagnosed VEDS, the danger of lack of clinical knowledge among first responders amplifies the risks. In the case of 12-year old – undiagnosed Natalie Paquette – the results were tragic. “Because Natalie’s heart rate was mainly stable initially, first responders bypassed a hospital ten minutes away and instead took Natalie to a children’s hospital 45 minutes away, unknowingly delaying crucial emergency treatment. Aortic dissection is typically diagnosed via a stat CT scan and treated via immediate surgery. Because of Natalie’s age, the first responders did not use lights nor sirens, trying to make an ambulance ride less stressful for a child nobody dreamed was experiencing a life-threatening aortic emergency.” Natalie lost her life due to a series of unfortunate events – but at the center of her death lies a common cause – lack of clinical knowledge.

The nature of VEDS requires that healthcare providers treat these patients with extraordinary caution. Imaging scans and other diagnostic tools can help detect arterial ruptures or other vascular issues, but they must be used quickly and appropriately. Without a clear understanding of VEDS and its risks, physicians may not order the necessary tests or provide the proper treatment, leading to tragic and avoidable deaths.

Shift Subtype Thinking Toward Life-Saving Action

To elevate VEDS patient care, the medical community must take steps to ensure that this condition is no longer seen as just another subtype. EDS reclassifying in 2017 was a step forward in many ways, but it inadvertently created a blind spot regarding Vascular EDS. A stronger focus on education in medical school and continuing professional development is urgently needed. Emergency room doctors, vascular specialists, and primary care physicians must all be aware of the dangers posed by VEDS and be prepared to act swiftly when patients appear with symptoms that mimic other conditions – even flu or GI upset.

Vascular EDS patients are accessing tools to advocate for themselves in medical settings. Medical alert bracelets and cards, detailed medical records, and clear communication with health providers are all essential for ensuring that patients receive the care they need when needed.

But systemic change is urgent and essential. The medical community must reevaluate how rare diseases like VEDS are classified and treated—how that knowledge trickles down into the emergency services and room response. Rather than grouping VEDS with other EDS subtypes, medical guidelines, educational materials, and clinical protocols should place greater emphasis on its life-threatening nature and, not unexpectedly, listening to the patient. This will ensure that physicians understand the gravity of VEDS and treat it with urgency.

Lives Depend on an Updated Perspective

Groups such as the American Heart Association echo the concerns of The Marfan Foundation and the VEDS community and have suggested that “it is important to create guidelines for the management and surveillance of individuals with vEDS.”

The current classification system for Ehlers-Danlos Syndrome is well-intentioned. However, the risks underrepresenting the severity of VEDS are concerning. By continuing to treat VEDS as another subtype of a broader condition, it is likely that physicians unintentionally may diminish the seriousness of a life-threatening genetic disorder that can and does kill. When arriving in the ER, VEDS patients or family members often know the risks and communicate concerns. This condition must be better understood in medical education and clinical practice. Lives depend on it.

The post Reevaluating Ehlers-Danlos Syndrome: How Vascular EDS Patients Are Left Behind appeared first on Medika Life.